In short
This article discusses a clinical trial investigating the effectiveness of Nicotine Resinate lozenges in reducing cravings for moderate smokers in non-smoking situations. The study aims to assess the impact of a 1.5mg nicotine lozenge compared to a placebo on smoking urges and withdrawal symptoms. This research is crucial for developing better smoking cessation aids and helping individuals quit smoking more effectively.
At a glance
- Study Type
- Randomized, double-blind, placebo-controlled parallel groups trial
- Intervention
- Nicotine Resinate 1.5mg lozenge vs. Placebo
- Participants
- Moderate smokers (11-20 cigarettes/day), aged 18+, motivated to quit
- Primary Outcome
- Reduction in smoking urges measured by QSU-brief score at 30 minutes
- Secondary Outcomes
- Craving reduction at 45, 60, 90 minutes; withdrawal symptoms; overall satisfaction
- Duration
- 24-hour confinement with 3-day follow-up
- Maximum Daily Dose
- Up to 20 lozenges (31.5mg nicotine) over 12 hours
- Safety Monitoring
- Adverse events, physical examinations, vital signs
What is Nicotine Resinate?
Nicotine Resinate is an active ingredient used in smoking cessation products, specifically in lozenges designed to help people quit smoking. It is a form of nicotine that is bound to a resin, which allows for a controlled release of nicotine when the lozenge dissolves in the mouth. The product being studied is called "NICOPASS 1.5 mg SANS SUCRE MENTHE FRAICHEUR," which is a sugar-free, fresh mint flavored lozenge.
How Does It Work?
Nicotine Resinate works by providing a small, controlled dose of nicotine to help reduce cravings and withdrawal symptoms that occur when a person stops smoking. When you use a Nicotine Resinate lozenge, it slowly releases nicotine into your body through the lining of your mouth. This helps to satisfy the body's craving for nicotine without the harmful effects of smoking tobacco.
Who Can Use Nicotine Resinate?
Nicotine Resinate lozenges are designed for moderate smokers who are trying to quit. Based on the clinical trial information, the ideal candidates for this treatment are:
- Adults aged 18 years or older
- Moderate smokers (11-20 cigarettes per day)
- Those with a Fagerström score of 5 to 6 (This is a test that measures nicotine dependence)
- People who smoke their first cigarette between 5 and 30 minutes after waking up
- Those with a high motivation to quit smoking (scoring >7 on the Richmond test)
How to Use Nicotine Resinate
Based on the clinical trial protocol, here's how Nicotine Resinate lozenges are typically used:
- Take the first lozenge about 30 minutes after breakfast.
- Allow the lozenge to dissolve slowly in your mouth. Do not chew or swallow it whole.
- Use additional lozenges throughout the day when you feel the urge to smoke.
- Wait at least 30 minutes between lozenges.
- Do not use more than 20 lozenges per day.
Effectiveness
The clinical trial aims to assess how effective Nicotine Resinate lozenges are in reducing cravings for cigarettes. The researchers are particularly interested in:
- How quickly the lozenges work (from 30 minutes up to 3 hours after use)
- How well they reduce cravings throughout the day
- Their effect on withdrawal symptoms such as anxiety, anger, irritability, difficulty concentrating, restlessness, and depressed mood
Side Effects and Safety
While Nicotine Resinate is generally considered safe for most people trying to quit smoking, it may not be suitable for everyone. The clinical trial excludes people with certain conditions, including:
- Phenylketonuria (a genetic disorder that affects how the body processes protein)
- Recent history of heart problems or stroke
- Epilepsy
- Asthma or COPD (Chronic Obstructive Pulmonary Disease)
- Parkinson's disease
- Oral health issues
- Pregnancy or breastfeeding
- Certain other medical conditions
Always consult with your healthcare provider before starting any new smoking cessation treatment.
Clinical Trial Information
The information provided is based on a clinical trial studying the effects of Nicotine Resinate lozenges. Key points about the trial include:
- It's a Phase III clinical trial, which means the treatment has already shown promise in earlier studies.
- It's a randomized, double-blind, placebo-controlled study. This means participants are randomly assigned to either the real treatment or a placebo, and neither the participants nor the researchers know who is getting which until the study is over.
- The study aims to evaluate how well the lozenges work to reduce cravings and withdrawal symptoms in moderate smokers who are trying to quit.
- The trial is specifically looking at the effects of a 1.5mg nicotine lozenge compared to a placebo.
Remember, while this information is promising, the full results of the clinical trial are not yet available. Always follow the advice of your healthcare provider when considering smoking cessation methods.